Mild-moderate Alzheimer's Disease

Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

DP
Daehwa PharmaceuticalKorea - Gangwon
1 program
1
DonepezilPhase 21 trial
Active Trials
NCT03055741Completed180Est. Aug 2019
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
MEDI1814 for IV injectionPhase 11 trial
Active Trials
NCT02036645Completed77Est. Sep 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daehwa PharmaceuticalDonepezil
AstraZenecaMEDI1814 for IV injection

Clinical Trials (2)

Total enrollment: 257 patients across 2 trials

Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)

Start: Dec 2016Est. completion: Aug 2019180 patients
Phase 2Completed
NCT02036645AstraZenecaMEDI1814 for IV injection

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Start: Feb 2014Est. completion: Sep 201677 patients
Phase 1Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space